GILD

SELL

Gilead Sciences, Inc.

Healthcare · Rank #372 · Analyzed Oct 18, 2026

$156.19

Current Price

$178.98

Intrinsic Value

+14.6%

Upside/Downside

1.8/10

Score

1.8/5

Quality

Analysis Summary

Valuation Consensus1/2 methods agree

Quality Score1.8/5.0

Framework RatingSELL

Price vs Intrinsic ValueUndervalued by 14.6%

Fair Value Range

Low$64.76

Base (IV)$178.98

High$268.46

Entry Points

Conservative$45.33

Moderate$64.76

Aggressive$125.28

⚠️ Warnings

Biotech/pharma: negative margins from R&D — using forward estimates

Quality & Moat Breakdown

Return on Equity-20.7% → 0/1.0

Debt LevelD/E 223 → 0/1.0

Revenue QualityGrowth -0.3%, margin Δ+12.3% +recovery → 0.5/1.0

Moat Strength4.0/5 → 1.0/1.0

Profit Margins-10.6% → 0.25/1.0

Methodology

This analysis uses a unified valuation framework combining three methods, Discounted Cash Flow (3-scenario), Earnings Power Value, and Asset Valuation, with a quality scoring overlay. A stock needs 2/3 valuation methods to agree and a quality score ≥ 3.5/5 for a BUY rating.

Learn how this framework works →

This is a personal analysis tool, not financial advice. Do your own research before making investment decisions.